Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Rangering i aksjer #39039
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Aksjekurs
$0.38
Sist synkronisert: 2023-09-01
Markedsverdi
$677.16K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Aceragen, Inc. (ACGN)

Kategori

EPS for Aceragen, Inc. (ACGN)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Aceragen, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Aceragen, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter